Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's Chief Executive Officer, John S. Yu, M.D., will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.
The virtual summit is scheduled to take place from October 15 to 17, 2024. Kairos Pharma's fireside chat is set for Thursday, October 17, 2024, at 1:00 PM ET. Interested parties can access the webcast of the event through the provided link: https://m-vest.com/events/healthcare-10152024.
This participation offers an opportunity for Kairos Pharma to share insights and updates with the investment community, potentially discussing their ongoing clinical-stage research and development in the biopharmaceutical sector.
Kairos Pharma (NYSE American: KAPA), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il Chief Executive Officer della compagnia, John S. Yu, M.D., parteciperà a una conversazione informale con Jason McCarthy, Ph.D., Direttore Generale e Responsabile della Ricerca Biotecnologica presso Maxim Group.
Il summit virtuale si svolgerà dal 15 al 17 ottobre 2024. La conversazione informale di Kairos Pharma è programmata per giovedì 17 ottobre 2024, alle 13:00 ET. Le parti interessate possono accedere alla diretta dell'evento tramite il link fornito: https://m-vest.com/events/healthcare-10152024.
Questa partecipazione rappresenta un'opportunità per Kairos Pharma di condividere approfondimenti e aggiornamenti con la comunità degli investitori, discutendo potenzialmente della loro ricerca e sviluppo in fase clinica nel settore biofarmaceutico.
Kairos Pharma (NYSE American: KAPA), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. El Director Ejecutivo de la compañía, John S. Yu, M.D., participará en una charla informal con Jason McCarthy, Ph.D., Director General y Jefe de Investigación en Biotecnología en Maxim Group.
La cumbre virtual está programada para llevarse a cabo del 15 al 17 de octubre de 2024. La charla informal de Kairos Pharma está programada para el jueves 17 de octubre de 2024, a la 1:00 PM ET. Las partes interesadas pueden acceder a la transmisión del evento a través del enlace proporcionado: https://m-vest.com/events/healthcare-10152024.
Esta participación ofrece a Kairos Pharma la oportunidad de compartir ideas y actualizaciones con la comunidad inversora, discutiendo potencialmente su investigación y desarrollo en fase clínica en el sector biofarmacéutico.
카이로스 제약 (NYSE American: KAPA), 임상 단계의 생물 의약품 회사,는 2024 맥심 헬스케어 가상 정상 회담에 참여한다고 발표했습니다. 회사의 CEO인 존 S. 유, M.D.가 제이슨 맥카시, Ph.D.와 함께 비공식 대화에 참여합니다. 제이슨 맥카시는 맥심 그룹의 생명공학 연구 책임자입니다.
가상 정상 회담은 2024년 10월 15일부터 17일까지 진행될 예정입니다. 카이로스 제약의 비공식 대화는 2024년 10월 17일 목요일, 오후 1시 ET로 예정되어 있습니다. 관심 있는 분들은 제공된 링크를 통해 이벤트의 웹캐스트에 접근할 수 있습니다: https://m-vest.com/events/healthcare-10152024.
이 참여는 카이로스 제약이 투자 커뮤니티와 통찰력과 업데이트를 공유할 기회가 되며, 생물 의약품 부문에서 진행 중인 임상 단계의 연구 및 개발에 대해 논의할 수 있는 기회를 제공합니다.
Kairos Pharma (NYSE American: KAPA), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le PDG de l'entreprise, John S. Yu, M.D., participera à une discussion informelle avec Jason McCarthy, Ph.D., Directeur Général et Responsable de la Recherche en Biotechnologie chez Maxim Group.
Le sommet virtuel est prévu du 15 au 17 octobre 2024. La discussion informelle de Kairos Pharma est fixée au jeudi 17 octobre 2024, à 13h00 ET. Les parties intéressées peuvent accéder au webcast de l'événement via le lien fourni : https://m-vest.com/events/healthcare-10152024.
Cette participation offre à Kairos Pharma l'opportunité de partager des idées et des mises à jour avec la communauté des investisseurs, discutant potentiellement de leurs recherches et développements en phase clinique dans le secteur biopharmaceutique.
Kairos Pharma (NYSE American: KAPA), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt gegeben. Der Geschäftsführer des Unternehmens, John S. Yu, M.D., wird in einem informellen Gespräch mit Jason McCarthy, Ph.D., dem Senior Managing Director und Leiter der Biotechnologieforschung bei Maxim Group, auftreten.
Der virtuelle Gipfel ist für den 15. bis 17. Oktober 2024 geplant. Das informelle Gespräch von Kairos Pharma findet am Donnerstag, den 17. Oktober 2024 um 13:00 Uhr ET statt. Interessierte Parteien können über den bereitgestellten Link auf den Webcast der Veranstaltung zugreifen: https://m-vest.com/events/healthcare-10152024.
Diese Teilnahme bietet Kairos Pharma die Gelegenheit, Erkenntnisse und Neuigkeiten mit der Investoren-Community auszutauschen und möglicherweise über ihre laufenden klinischen Forschungs- und Entwicklungsaktivitäten im biopharmazeutischen Sektor zu diskutieren.
- None.
- None.
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he will be speaking with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.
| Event: | Fireside Chat at 2024 Maxim Healthcare Virtual Summit |
| Date: | Thursday, October 17, 2024 |
| Time: | 1:00 PM ET |
| Webcast: | https://m-vest.com/events/healthcare-10152024 |
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. By inhibiting CD105 on cancer cell surfaces, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer, addressing significant unmet medical needs. For more information, visit kairospharma.com.
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.
Contact:
CORE IR
Louie Toma
investors@kairospharma.com
FAQ
When is Kairos Pharma (KAPA) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Kairos Pharma (KAPA) at the 2024 Maxim Healthcare Virtual Summit?
What type of event will Kairos Pharma (KAPA) participate in at the 2024 Maxim Healthcare Virtual Summit?
How can investors access Kairos Pharma's (KAPA) fireside chat at the 2024 Maxim Healthcare Virtual Summit?
What is the date range for the 2024 Maxim Healthcare Virtual Summit featuring Kairos Pharma (KAPA)?
